文献速递前列腺癌

MRI与靶向活检对MRI阳性前列腺癌主动监测候选者的影响

Impact of MRI and Targeted Biopsies on Eligibility and Disease Reclassification in MRI-positive Candidates for Active Surveillance on Systematic Biopsies.
PubMed 文献 · Urology · 2019-12-30

本研究纳入在系统活检下符合主动监测(AS)标准的MRI阳性低危前列腺癌患者,所有患者均接受系统活检联合软件融合靶向活检并立即行根治性前列腺切除术。结果显示靶向活检可预测最终分级升级,但不同AS标准下疾病再分类风险相当,且约三分之一患者存在病理分期升级,现有参数难以准确预测。

要点

  • MRI阳性患者中,无论采用哪种系统活检AS标准,疾病再分类风险相当。
  • 靶向活检阴性强烈提示最终无GG≥3疾病,但其预测价值因AS标准而异。
  • 约三分之一患者根治标本存在非器官局限性疾病,现有参数难以准确预测。

核心结论

  • 在MRI阳性患者中,无论采用哪种基于系统活检的AS标准,疾病再分类风险相当。
  • 靶向活检可预测最终分级升级,但其影响因AS标准不同而异。
  • 即使靶向活检阳性,系统活检特征对再分类预测仍有意义。
  • 病理分期升级风险仍高,约三分之一,且靶向/系统活检参数及MRI表现均无法准确预测。

研究设计与样本

  • 前瞻性数据库纳入活检前MRI阳性、系统活检符合AS标准(Toronto n=114、UCSF n=82、PRIAS n=60)的患者。
  • 所有患者接受系统活检联合软件融合靶向活检,并立即行根治性前列腺切除术。
  • 主要终点为病理分级升级和分期升级率。

主要发现

  • 靶向活检将活检分级组升级至GG2的比例为65.9%-76.7%,升级至GG≥3的比例为12.2%-16.7%。
  • 根治性前列腺切除标本中GG≥3的比例为31.6%-43.3%,最严格标准与更低升级率无关。
  • 非器官局限性疾病比例为35%-39%,各AS队列间相当。
  • 靶向活检阴性强烈与最终无GG≥3疾病相关。

临床怎么用

  • MRI阳性且系统活检符合AS标准的患者,无论采用哪种标准,均应警惕约三分之一的分期升级风险。
  • 靶向活检结果可用于辅助预测分级升级,但需结合系统活检特征综合评估。
  • 靶向活检阴性可降低对最终GG≥3疾病的担忧,但仍需注意分期升级可能。

局限性

  • 不同AS标准队列间样本量不均,可能影响比较。
  • 未报告其他潜在预测因素及长期随访结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the impact of concomitant targeted biopsies (TB) for predicting final disease reclassification in MRI-positive low-risk prostate cancer patients eligible for active surveillance (AS) on systematic biopsies (SB). MATERIALS AND METHODS: From a prospective database, we included all prebiopsy MRI-positive men fulfilling AS criteria at diagnosis (Toronto [n = 114], UCSF [n = 82], or PRIAS [n = 60] criteria) on SB. All patients underwent a combination of SB and software-based fusion TB, and an immediate radical prostatectomy. The primary endpoints were the pathologic upgrading and upstaging rates. RESULTS: Biopsy grade group was upgraded to grade group (GG) 2 and to GG≥3 on TB in 65.9%-76.7% and in 12.2-16.7%, respectively. The rate of GG ≥3 in radical prostatectomy specimens varied from 31.6% to 43.3% with no relation between strictest criteria and lower upgrading rates. The proportion of not organ-confined disease (35%-39%) was comparable among the AS cohorts. Negative TB was strongly associated with the absence of final GG ≥3. Tumor grade on TB was significantly correlated with the risk of final GG ≥3 in both Toronto and UCSF cohorts, not in the PRIAS cohort. In the PRIAS cohort, the only independent predictive factor for GG ≥3 disease was the maximal tumor length in any core (P = .034). CONCLUSION: In MRI-positive patients, the risk of disease reclassification was comparable whatever the SB-based AS criteria used. TB were predictive of final upgrading, with a varied impact according to the AS criteria. SB features remained relevant for reclassification prediction even in case of positive TB. The risk of upstaged disease remains important, approximately one third, and neither TB/SB parameters nor MRI findings could accurately predict it.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Ploussard G, Beauval JB, Lesourd M, et al. Impact of MRI and Targeted Biopsies on Eligibility and Disease Reclassification in MRI-positive Candidates for Active Surveillance on Systematic Biopsies. Urology. 2019. PMID: 31899229. doi:10.1016/j.urology.2019.10.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。